We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
New research labs and process development services to enable next generation therapeutics
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subscribe To Our Newsletter & Stay Updated
